Jodi Jahic

Director at Zero Point Five Therapeutics

Capital raised by Zero Point Five Therapeutics

$4.3M+$4.3M latest round

1 Form D filing · first filed Apr 2025 · Baltimore, MD

CURRENT ROLE: Director
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

Zero Point Five TherapeuticsBiotech · Baltimore, MDsince Apr 2025

Director

Listed on Zero Point Five Therapeutics's Form D filings

Company filings

via EDGAR · Form D for Zero Point Five Therapeutics1

DateCompanyFormAmountRole on filing

Apr 2, 2025Zero Point Five TherapeuticsForm D+$4.3M—

Form DApr 2, 2025 · Zero Point Five Therapeutics+$4.3Mnot a signer

Overview

Last filing Apr 2, 2025

Jodi Jahic is on file as Director at Zero Point Five Therapeutics in Baltimore, MD. Zero Point Five Therapeutics has 1 Form D filing on record, $4.3M raised in total.

Teammates

Zero Point Five Therapeutics · 1

Joseph Amprey IIIChief Executive OfficerSigner

Products

Zero Point Five Therapeutics · 1

ZP5-9676Pharmaceuticals

ZP5-9676 is a drug candidate based on flubendazole and is currently in Phase 3 clinical trials, aimed at treating infections caused by soil-transmitted helminths including hookworm, roundworm, and whipworm.